Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Zenaida Mojares"'
Autor:
Phirangkul Kerdpanich, Pornthep Chanthavanich, Mari Rose De Los Reyes, Jodor Lim, Delia Yu, Ma Cecilia Ama, Zenaida Mojares, Daniela Casula, Ashwani Kumar Arora, Michele Pellegrini
Publikováno v:
PLoS Neglected Tropical Diseases, Vol 12, Iss 6, p e0006340 (2018)
This phase III clinical trial compared the immunogenicity and safety of a purified chick-embryo cell rabies vaccine (PCECV) administered according to a shortened post-exposure prophylaxis (PEP) 4-site/1-week intradermal regimen, compared with the cur
Externí odkaz:
https://doaj.org/article/5a4dc1cee2d24b84a83bdd13b14f40ab
Autor:
Vianney Tricou, Susannah Eyre, Mahadev Ramjee, Paul Collini, Zenaida Mojares, Edde Loeliger, Sanja Mandaric, Martina Rauscher, Manja Brose, Inge Lefevre, Nicolas Folschweiller, Derek Wallace
Publikováno v:
Vaccine. 41:1398-1407
Autor:
Shibadas, Biswal, Humberto, Reynales, Xavier, Saez-Llorens, Pio, Lopez, Charissa, Borja-Tabora, Pope, Kosalaraksa, Chukiat, Sirivichayakul, Veerachai, Watanaveeradej, Luis, Rivera, Felix, Espinoza, LakKumar, Fernando, Reynaldo, Dietze, Kleber, Luz, Rivaldo, Venâncio da Cunha, José, Jimeno, Eduardo, López-Medina, Astrid, Borkowski, Manja, Brose, Martina, Rauscher, Inge, LeFevre, Svetlana, Bizjajeva, Lulu, Bravo, Derek, Wallace, Zenaida, Mojares
Publikováno v:
New England Journal of Medicine. 381:2009-2019
Dengue, a mosquito-borne viral disease, was designated a World Health Organization top 10 threat to global health in 2019.We present primary efficacy data from part 1 of an ongoing phase 3 randomized trial of a tetravalent dengue vaccine candidate (T
Autor:
Zenaida Mojares, Peter Richmond, Sepehr Shakib, Sharon E. Frey, Bikash Verma, Timothy W. Smith, Matthew Hohenboken, Claudia Kittel, Peter Jaehnig, Terapong Tantawichien, Pornthep Chanthavanich, Niranjan Kanesa-thasan
Publikováno v:
Open Forum Infectious Diseases
Background A/H5N1 influenza viruses have high pandemic potential; consequently, vaccines need to be produced rapidly. MF59® adjuvant reduces the antigen required per dose, allowing for dose sparing and more rapid vaccine availability. Methods Two mu
Autor:
Mari Rose De Los Reyes, Zenaida Mojares, Ma. Cecilia G. Ama, Delia Yu, Michele Pellegrini, Jodor Lim, Ashwani Kumar Arora, Daniela Casula, Phirangkul Kerdpanich, Pornthep Chanthavanich
Publikováno v:
PLoS Neglected Tropical Diseases
PLoS Neglected Tropical Diseases, Vol 12, Iss 6, p e0006340 (2018)
PLoS Neglected Tropical Diseases, Vol 12, Iss 6, p e0006340 (2018)
Background This phase III clinical trial compared the immunogenicity and safety of a purified chick-embryo cell rabies vaccine (PCECV) administered according to a shortened post-exposure prophylaxis (PEP) 4-site/1-week intradermal regimen, compared w